The rate of patients enrolled per site per month in oncology Phase 3 trials declined by 14% between 2012β2023. In non-oncology trials, that decline was 54%.
McKinsey, 2024
The 5 Recruitment Failures Hekma Solves
95% of traditional recruitment comes from investigators referring their own patients. Hekma breaks site dependency β finding patients outside your network through EHR matching, PAG communities, and digital channels.
60% of referred patients fail screening. Hekma AI summarisation pre-screens every candidate against your specific I/E criteria β only likely-eligible patients reach your sites.
3% Black, <2% Asian-American, <5% Latino trial participants. FDA now requires diversity action plans. Hekma EHR network and PAG partnerships specifically reach underrepresented communities.
No sites see a lot of ultra-rare patients. Hekma H360 rare disease patient database and PAG partnerships in rare disease communities find patients no site network can reach.
Submit protocol to CRO and wait weeks for a site activation report. Hekma gives you a real-time dashboard showing your patient funnel β updated continuously.
The Diversity Gap
3%
Black trial participants
Despite double the prostate cancer incidence vs white Americans
<2%
Asian-American participants
Significantly underrepresented across all trial phases
<5%
Latino participants
Despite representing 18% of the US population
Compliance & Standards
Five recruitment failures. One platform that solves all of them.